How many drugs treat Ebola virus disease?

Drug Landscape tracks 6 marketed treatments for Ebola virus disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/ebola-virus-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ebola virus disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ebola virus disease (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Ebola virus disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Inmazeb	ATOLTIVIMAB	Regeneron		Low affinity immunoglobulin gamma Fc region receptor III-A	2020-01-01
Inmazeb	ODESIVIMAB	Regeneron		Low affinity immunoglobulin gamma Fc region receptor III-A	2020-01-01
Inmazeb	MAFTIVIMAB	Regeneron			2020-01-01
Ebov Mab114	ANSUVIMAB	Ridgeback Biotherapeutics	Zaire Ebolavirus Glycoprotein-directed Antibody		2020-01-01
Inmazeb	Inmazeb	ANRS, Emerging Infectious Diseases		Low affinity immunoglobulin gamma Fc region receptor III-A, Envelope glycoprotein
EBANGA	ANSUVIMAB-ZYKL	RIDGEBACK BIOTHERAPEUTICS		Envelope glycoprotein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Regeneron · 3 drugs in Ebola virus disease
ANRS, Emerging Infectious Diseases · 1 drug in Ebola virus disease
RIDGEBACK BIOTHERAPEUTICS · 1 drug in Ebola virus disease
Ridgeback Biotherapeutics · 1 drug in Ebola virus disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Ebola virus disease:

Cite this brief

Drug Landscape (2026). Ebola virus disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ebola-virus-disease. Accessed 2026-06-10.

Ebola virus disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing